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Anti-IL-1β antibodies conjugated with DSPE-PEG-NHS
Anti-IL-1β antibodies, Gevokizumab, were first reacted with DSPE-PEG-NHS through -NH 2 and NHS acylation reactions. Equimolar antibodies and DSPE-PEG-NHS were mixed together and reacted at 4°C for 24 h. Then, the unreacted DSPE-PEG-NHS was removed by centrifugation using an Amicon Ultra-0.5 Filter (100kDa). Successful conjugation was confirmed by SDS-PAGE.
Denuded rat aorta binding assay
To examine the binding of IL1-PM onto injured (denuded) vascular walls, aortas from C57BL/6 mice were dissected and surgically scraped on their luminal side with forceps, to remove the endothelial layer. Both denuded or control aortas were incubated with DiO-labeled IL1-PM for for IL1-PM binding.
Aggregation assay
To determine if IL1-PM induced any adverse pro-thrombotic effects, 450 μL of platelet poor plasma (PRP) was collected and added to glass cuvettes for aggregometry. Aggregometry was performed using a commercial optical (light transmission) aggregometer (Chrono-log 700 manual, Chrono-log Corp.). The following analyses were performed: (1) freshly prepared PRP with PBS; (2) freshly prepared PRP with IL1-PM.
Animal experiments
All animal work was compliant with the Institutional Animal Care and Use Committee (IACUC) of North Carolina State University. MI mice were randomized into four treatment groups (n = 10 mice per group): 1) i.v. injection of 100 μL PBS; 2) i.v. injection of 10 8 bare platelets in 100 μL PBS; 3) i.v. injection of anti-IL-1β antibodies at a dose of 2 mg antibodies/kg mouse body weight; and 4) i.v. injection of IL1-PM at a dose of 2 mg antibodies/kg mouse body weight.
Five out of ten mice were sacrificed and the blood and heart tissues were harvested after 3 days of treatment and used for cytokine, western blot, and ELISA analysis. The transthoracic echocardiography procedure was performed with a Philips CX30 ultrasound system, coupled with a L15 high-frequency probe, by a cardiologist blinded to animal group allocation. All animals inhaled a 1.5% isoflurane-oxygen anesthesia mixture in the supine position at the 4-hr, 28 day and 70 day time points (n = 5 mice per group). Hearts were imaged in 2D in long-axis views at the level of the greatest left ventricular (LV) diameter. Ejection fraction (EF) was determined by measurements from views taken from the infarcted area. Left ventricular end diastolic volume (LVEDV) and end systolic volume (LVESV) were measured. LVEF was determined by measurement from views taken from the infarcted area. Finally, animals were sacrificed 70 days after injection and hearts were harvested and frozen in OCT compound.
Specimens were sectioned at 10 μm thicknesses from the apex to the ligation level with 100 μm intervals. Masson's trichrome staining was performed as described by the manufacturer's instructions. Images were acquired with a PathScan Enabler IV slide scanner (Advanced Imaging Concepts, Princeton, NJ). From the Masson's trichrome stained images, morphometric parameters, including viable myocardium, scar size, and infarct thicknesses were measured in each section with NIH ImageJ software. The percentage of viable myocardium as a fraction of the scar area (infarcted size) was quantified. Three selected sections were quantified for each animal.
Western blot and ELISA analysis
The hearts harvested after the 3 rd day of treatments were homogenized in RIPA buffer and supplemented with a protease inhibitor cocktail. The obtained solutions were centrifuged at 16,000 x g for 20 min to remove non-homogenized tissue. Then, the total protein concentration was measured using a BCA Protein Assay Kit. After that, the CD45, caspase-1, and caspase-3 were analyzed using western blot. In addition, Caspase-1 Assay Kit (Fluorometric) was used for detecting the activity of caspases that recognized the sequence YVAD using the fluorometric method. Caspase-3 substrate Ac-DEVD-pNA was applied to detect the caspase-3 activities in the heart using colorimetric analysis kits according to the manufacturer's instructions.
Furthermore, the change of IL-1β was detected using a mouse anti-IL-1β kit, according to the manufacturer's instructions.
Immunohistochemistry assessment
Heart cryosections were fixed with 4% paraformaldehyde in PBS for 30 min, permeabilized, and blocked with Protein Block Solution (DAKO) containing 0.1% saponin for 1 h, at room temperature. The cryosections were then immunoassayed with anti-ASC antibodies to detect the presence of inflammasome, and with TUNEL to quantify cardiomyocyte apoptosis. In addition, anti-mouse alpha sarcomeric actin antibodies were used to co-stain and identify cardiomyocytes. Furthermore, anti-CD3 (T cells) and F4/80 (macrophages) antibodies were used to test the immune response in the heart. For IHC study, hearts were cryo-sectioned at 10 μm thickness from the apex to the ligation level with 100 μm intervals for immunohistochemistry Four slides were stained for each animail and 4 randomly selected fields from each slide (n = 4) were analyzed with NIH ImageJ software. The red, green, and blue channels were split (RGB), and the integrated densities of the green signal were calculated using the software. 
